A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma Journal Article


Authors: Berg, W. J.; McCaffrey, J.; Schwartz, L. H.; Mariani, T.; Mazumdar, M.; Motzer, R. J.
Article Title: A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma
Abstract: The aim of this study was to determine the antitumor activity of pyrazoloacridine in patients with renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases. Patients were treated intravenously with 750 mg/m2 every three weeks. Twelve patients were enrolled in this study and all were evaluable for response and toxicity. Of the twelve patients, no major responses were achieved. Toxicity was mild, with three patients requiring a 20% dose reduction. At the dose and schedule used in this trial, pyrazoloacridine is inactive in renal cell carcinoma.
Keywords: adult; clinical article; aged; middle aged; unclassified drug; clinical trial; neutropenia; advanced cancer; antineoplastic agents; phase 2 clinical trial; blood toxicity; leukopenia; antineoplastic activity; kidney carcinoma; kidney neoplasms; carcinoma, renal cell; pyrazoles; drug toxicity; life expectancy; acridine derivative; acridines; 2 (2 dimethylaminoethyl) 9 methoxy 5 nitropyrazolo[3,4,5 kl]acridine; humans; prognosis; human; male; female; priority journal; article; advanced renal cell carcinoma; pyrazoloacridine
Journal Title: Investigational New Drugs
Volume: 16
Issue: 4
ISSN: 0167-6997
Publisher: Springer  
Date Published: 1998-12-01
Start Page: 337
End Page: 340
Language: English
DOI: 10.1023/A:1006143008040
PUBMED: 10426668
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 12 December 2016 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Robert Motzer
    1172 Motzer
  2. Madhu Mazumdar
    127 Mazumdar
  3. William J Berg
    16 Berg
  4. Lawrence H Schwartz
    290 Schwartz